Zoladex 3.6mg Implant Wholesale USA: Ernest Impex – Verified India Exporter

Zoladex 3.6 mg Implant – Advanced Hormonal Therapy | Global Bulk Supply by Ernest Impex

Zoladex 3.6 mg (Goserelin Acetate) is a potent LHRH (luteinizing hormone-releasing hormone) agonist used in the management of hormone-sensitive cancers and various gynecological conditions. As a premier pharmaceutical exporter from India, Ernest Impex (Group of Ernest Pharmaceutical Pvt. Ltd.) provides specialized temperature-controlled logistics and wholesale distribution to Washington (USA), London (UK), Canberra (Australia), Bangkok (Thailand), Kingston (Jamaica), and Singapore.

Comprehensive Product Information: Zoladex 3.6 mg

1. Composition and Delivery System

Zoladex 3.6 mg is unique because it is not a traditional tablet or liquid injection. It is supplied as a biodegradable depot implant in a pre-filled, ready-to-use syringe.

• Active Ingredient: Goserelin Acetate (equivalent to 3.6 mg of goserelin).

• Format: A small, thin rod-like implant designed for subcutaneous injection.

• Duration: Designed to release the medication continuously over a 28-day period.

2. Therapeutic Indications

Zoladex 3.6 mg is a versatile hormonal therapy indicated for the following:

• Prostate Cancer: For the palliative treatment of advanced prostate cancer.

• Breast Cancer: Used in premenopausal and perimenopausal women with advanced breast cancer suitable for hormonal manipulation.

• Endometriosis: For the management of endometriosis, helping to reduce pain and lesion size.

• Uterine Fibroids: Used in conjunction with surgery to reduce the size of fibroids and improve the patient's hematological status.

• Assisted Reproduction: To desensitize the pituitary gland in preparation for superovulation.

3. Mechanism of Action (How It Works):

Goserelin is a synthetic analogue of naturally occurring LHRH. Initially, Zoladex causes a temporary increase in the production of serum testosterone (in men) and estrogen (in women). However, with continuous administration, it leads to the down-regulation of pituitary LHRH receptors.

This results in a significant drop in the production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Consequently, testosterone or estrogen levels fall to "castrate" levels, effectively "starving" hormone-dependent tumors.

4. Dosage and Administration

• Standard Regimen: One 3.6 mg implant injected subcutaneously into the anterior abdominal wall every 28 days.

• Procedure: The implant is administered by a healthcare professional using the sterile, pre-filled applicator. Local anesthesia may be used but is often not required due to the specialized needle design.

• Long-term Use: For prostate and breast cancer, treatment is typically long-term, whereas for benign conditions (like endometriosis), it is usually limited to 6 months.

5. Safety Profile & Side Effects

Hormonal suppression can lead to specific physiological changes:

• Common Side Effects: Hot flashes, sweating, decreased libido, and injection site reactions (mild bruising or redness).

• Bone Health: Long-term use may lead to a reduction in bone mineral density.

• Monitoring: Patients should be monitored for changes in blood pressure and glucose tolerance.

• Storage: Store in a cool, dry place below 25°C. Do not remove the syringe from the sealed pouch until ready for use.